Trial · NCT07432425
Effects of Different Exercise Protocols on Physical and Cognitive Changes in People With Chronic Neck Pain
NCT07432425, Not applicable, Recruiting, Hacettepe University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Different Exercise Protocols on Physical and Cognitive Changes in People With Chronic Neck Pain. Trials, record NCT07432425. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07432425
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Different Exercise Protocols on Physical and Cognitive Changes in People With Chronic Neck Pain
- NCT number
- NCT07432425
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 21 participants, estimated
- Lead sponsor
- Hacettepe University
- Conditions
- Neck Pain, Chronic Neck Pain
- Interventions
- Aerobic exercise, Strengthening exercise, Posture and strentching exercise
- First posted
- 2026-02-25
- Last updated
- 2026-02-25
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pain Intensity | Baseline, 6th week, and 12th week | Numerical scales are among the frequently used one-dimensional pain intensity scales because they are easy to use and effective. In the application, volunteers are asked to choose the number that best describes their pain intensity. Zero indicates no pain, while 10 represents the worst pain imaginable. |
| Other | Global Cognition | Baseline and 12th week | Montreal Cognitive Assessment Test was developed as a rapid screening test for mild cognitive impairments. The Turkish validity and reliability study was conducted. Montreal Cognitive Assessment Test evaluates different cognitive performance areas including short-term memory, visuospatial abilities, executive functions, attention, concentration, working memory, language, orientation to time and place. The highest total score that can be obtained from the test is 30 points. |
| Other | Biochemical Measurements | Baseline and 12th week | Blood samples will be taken from the participants before and after the exercise treatment in order to observe the changes in blood biomarkers and to reveal the relationship between the masurements and serum levels of the biomarkers. Cortisol, Interleukin 1 Beta, Tumor Necrosis Factor Alpha, Insulin-Like Growth Factor-1, Interleukin-10, Irisin, Brain-Derived Neurotrophic Factor, Nerve Growth Factor and Cathepsin B will be measured in the blood samples taken before and after the exercise treatment. The blood samples taken will be stored at -80°C in a centrifuged manner until they are analyzed. 8 milliliters of blood will be taken from the participants. The serum will be studied and all parameters will be evaluated with the ELISA kit. |
| Other | Neuromaging | Baseline and 12th week | Brain structural and perfusion weighted imaging magnetic resonance images will be taken to observe changes in brain structure and functions before and after exercise treatment of participants to reveal the relationship between the measurements and brain changes. Structural images will consist of imaging in different sequences and planes (sagittal T1A, isovolumetric axial T1A, axial and coronal T2A, FLAIR (Fluid Attenuated Inversion Recovery), diffusion-weighted imaging, SWI (Susceptibility Weighted Imaging). The obtained radiological images will be analyzed in the FreeSurfer image processing program. After the images are processed with the FreeSurfer software, quantitative vertex-based processing will be used to obtain data such as cortical thickness, gray matter volume and cerebral blood flow in a highly sensitive manner. For each region of interest (ROI) in the Desikan-Killiany atlas, volume, cortical thickness, mean arterial time and cerebral blood flow data will be calculated. |
| Other | Cognitive Functions | Baseline and 12th week | Trail Making Test: It is used to evaluate selective and sustained attention, visual scanning, information processing speed, and executive functions. The Turkish standardization study of the test was conducted. The test has two parts, A and B. Part A of the test consists of randomly arranging the numbers in circles, and the participant is asked to combine the numbers in order and without lifting the pen. In part B, both the numbers and the letters are randomly arranged in circles. There is a simplified sample exercise section for each section. The participants is asked to combine the numbers and letters without lifting the pen and by paying attention to the order, so that one number becomes one letter. The time it takes the volunteer to complete each section will be recorded. |
| Other | Cognitive Functions | Baseline and 12th week | The Stroop Test is a brief measure of selective or focused attention, the ability to switch from one perceptual state to another in the test and to inhibit cognitive interference. It measures concentration and the ability to resist distractions. A Turkish standardization study was conducted and its norms were determined. |
| Other | Cognitive Functions | Baseline and 12th week | Standardized Mini Mental Test is used to determine cognitive level. The validity and reliability study of the test in Turkish was conducted. The scores that can be obtained from the test can vary between 0 and 30 points. The cut-off score for mild and moderate dementia in our country was reported as 23/24. |
| Other | Pittsburgh Sleep Quality Index | Baseline and 12th week | The Turkish validity and reliability of the scale were established. The scale is a 19-item scale consisting of 7 components that assess sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disorders, sleep medication use, and daytime functional impairment. Some components consist of a single item, while others are grouped together. Each item is scored between 0 and 3 points. The total scale score ranges from 0 to 21, with higher scores indicating poor sleep quality. |
| Other | Pressure Pain Thresholds | Baseline, 6th week, and 12th week | To objectively assess central sensitization, the pressure pain thresholds of the volunteers will be evaluated. A digital algometer will be used for this measurement. A symptomatic local region (middle trapezius muscle midway between the spinous process of C7 and the lateral border of the acromion) and at asymptomatic distant region (quadriceps muscle midway between the anterior superior iliac spine and the basis patellae) will be measured. |
| Other | Central Sensitization Inventory | Baseline and 12th week | This scale was developed for the purpose of evaluating central sensitization. The Turkish validity and reliability study of the scale was conducted. The scale consists of 2 sections, A and B. Section A consists of 25 questions that inquire about the frequency of symptoms that may be associated with central sensitization, while Section B inquires whether the patient has been diagnosed by a physician with a disease thought to be associated with central sensitization, and if so, on what date. Each question is scored from never (0) to always (4). The highest possible score on the scale is 100. An increase in the score on the scale indicates a more severe central sensitization. |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Other outcome | ConductCognition |
| Trail Making Test A | Other outcome | ConductCognition |
| Trail Making Test B | Other outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07432425
GET https://conductscience.org/api/trials/v1/NCT07432425/registered